All In Biotech

Drug Trial Radar · NCT05112601

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

81

Planned (sponsor's estimate)

Start

Jun 2, 2022

Primary completion

Jul 30, 2032

Study completion Jul 30, 2032

Sponsor

Sponsor type
NIH
Collaborators
NRG Oncology
First posted
Nov 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from gene mutation called Lynch Syndrome (previously called hereditary nonpolyposis colorectal cancer or HNPCC). MMR deficient cells usually have many DNA mutations. Tumors that have evidence of mismatch repair deficiency tend to be more sensitive to immunotherapy. There is some evidence that nivolumab with ipilimumab can shrink or stabilize cancers with deficient mismatch repair system. However, it is not known whether this will happen in endometrial cancer; therefore, this study is designed to answer that question. Monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with ipilimumab may be better than nivolumab alone in treating dMMR recurrent endometrial carcinoma.

Conditions

  • Endometrial Adenocarcinoma
  • Endometrial Clear Cell Adenocarcinoma
  • Endometrial Dedifferentiated Carcinoma
  • Endometrial Endometrioid Adenocarcinoma
  • Endometrial Mixed Cell Adenocarcinoma
  • Endometrial Mucinous Adenocarcinoma
  • Endometrial Undifferentiated Carcinoma
  • Endometrioid Adenocarcinoma
  • Recurrent Endometrial Carcinoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of tissue and/or blood samples

  • Computed TomographyProcedure

    Undergo CT

  • IpilimumabBiological

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • NivolumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years after randomization

Locations

138 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Recruiting

  • University Cancer and Blood Center LLC

    Athens, Georgia · Suspended

  • Augusta University Medical Center

    Augusta, Georgia · Recruiting

  • Saint Alphonsus Cancer Care Center-Boise

    Boise, Idaho · Suspended

  • Saint Luke's Cancer Institute - Boise

    Boise, Idaho · Recruiting

  • Saint Alphonsus Cancer Care Center-Caldwell

    Caldwell, Idaho · Suspended

  • Kootenai Health - Coeur d'Alene

    Coeur d'Alene, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Fruitland

    Fruitland, Idaho · Recruiting

  • Saint Luke's Cancer Institute - Meridian

    Meridian, Idaho · Recruiting

  • Saint Alphonsus Cancer Care Center-Nampa

    Nampa, Idaho · Suspended

  • Saint Luke's Cancer Institute - Nampa

    Nampa, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Post Falls

    Post Falls, Idaho · Recruiting

  • Kootenai Clinic Cancer Services - Sandpoint

    Sandpoint, Idaho · Recruiting

  • University of Illinois

    Chicago, Illinois · Suspended

  • Carle at The Riverfront

    Danville, Illinois · Recruiting

  • Carle Physician Group-Effingham

    Effingham, Illinois · Recruiting

  • Carle Physician Group-Mattoon/Charleston

    Mattoon, Illinois · Recruiting

  • Carle BroMenn Medical Center

    Normal, Illinois · Recruiting

  • Carle Cancer Institute Normal

    Normal, Illinois · Recruiting

  • Carle Cancer Center

    Urbana, Illinois · Recruiting

  • IU Health North Hospital

    Carmel, Indiana · Suspended

  • Northwest Cancer Center - Crown Point

    Crown Point, Indiana · Recruiting

  • Northwest Oncology LLC

    Dyer, Indiana · Recruiting

  • Northwest Cancer Center - Hobart

    Hobart, Indiana · Recruiting

  • Saint Mary Medical Center

    Hobart, Indiana · Recruiting

  • Indiana University/Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana · Recruiting

  • Saint Catherine Hospital

    Indianapolis, Indiana · Recruiting

  • The Community Hospital

    Munster, Indiana · Recruiting

  • Women's Diagnostic Center - Munster

    Munster, Indiana · Recruiting

  • Northwest Cancer Center - Valparaiso

    Valparaiso, Indiana · Recruiting

  • University of Iowa/Holden Comprehensive Cancer Center

    Iowa City, Iowa · Recruiting

  • The James Graham Brown Cancer Center at University of Louisville

    Louisville, Kentucky · Recruiting

  • UofL Health Medical Center Northeast

    Louisville, Kentucky · Recruiting

  • MaineHealth Maine Medical Center- Scarborough

    Scarborough, Maine · Recruiting

  • Bronson Battle Creek

    Battle Creek, Michigan · Recruiting

  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital

    Grand Rapids, Michigan · Recruiting

  • Trinity Health Grand Rapids Hospital

    Grand Rapids, Michigan · Suspended

  • Bronson Methodist Hospital

    Kalamazoo, Michigan · Recruiting

  • West Michigan Cancer Center

    Kalamazoo, Michigan · Recruiting

  • Beacon Kalamazoo Cancer Center

    Kalamazoo, Michigan · Recruiting

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.